Barely Significant
← all phrases

“a nonsignificant trend”

5,407 sentences · 5,407 papers · 7,516 search hits before verification · confirmed specimen

Sighted at

p<0.1

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

Cilengitide combination treatment showed a nonsignificant trend only in increasing OS in GB patients with unmethylated MGMT promoter, a finding that replicated the failure of Cilengitide to improve OS seen in the CENTRIC trial.[ 202 ] CENTRIC and CORE trials determined that there is no survival advantage for adding anti-αvβ3-αvβ5-integrin therapy (Cilengitide) to SOC for patients with newly diagnosed GB.
18 Subsequently reported 10‐year data, however, showed a nonsignificant trend for better outcomes in both men and women treated with CABG, and significant interaction between sex and revascularization strategy could no longer be detected. 19 In light of such results, sex has been eliminated as a component of the SYNTAX II score, a risk score meant to aid in the decision
In PPMS, a single study reported significantly less patients with EDSS progression in the IVIG-treated group than in the placebo group, with a nonsignificant trend to a delay in time to disease progression ( Pohlau et al., 2007 ).
Multiple Sclerosis
International Encyclopedia of Public Health · 2016 · PMC7149550
Dapagliflozin showed the largest reduction in composite renal outcomes, canagliflozin produced the most pronounced reduction in albuminuria, and both dulaglutide 1.5 mg and semaglutide demonstrated significant renal benefits, whereas exenatide showed only a nonsignificant trend.
31 However, it reported a significantly higher rate of any intracranial hemorrhage with IVT plus endovascular treatment (OR, 0.82 [95% CI, 0.68–0.99]), whereas our analysis showed a nonsignificant trend toward increased risk with IAT (OR, 1.30 [95% CI, 0.96–1.96]), indicating a potential safety concern that warrants further investigation.
20 The trial continued over 5 years, and demonstrated sustained benefit of early ART with both experimental arms performing better than deferred ART and a nonsignificant trend toward better outcomes with 96 weeks compared with 40 weeks of ART. 19 The CHAPAS-3 trial in Zambia and Uganda (2010–2014) was another 3-arm trial, powered for a toxicity primary endpoint comparing 3 nucleoside backbones in both ART-naive and virologically suppressed children on stavudine-based first-line ART (Fig. 1 B). 21 Factorial RCT A factorial trial simultaneously allows for 2 (or more) interventions, preferably targeting different aspects of a patient's disease, to be compared with standard treatment(s).